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ABSTRACT
Background. The aim of this study was to evaluate the effi-
cacy and safety of chemoradiotherapy (RCT) combined with
regional deep hyperthermia (RHT) of high-risk bladder cancer
after transurethral resection of bladder tumor (TUR-BT).
Materials and methods. Between 1982 and 2016, 369
patients with pTa, pTis, pT1, and pT2 cN0–1 cM0 bladder can-
cer were treated with a multimodal treatment after TUR-BT.
All patients received radiotherapy (RT) of the bladder and
regional lymph nodes. RCT was administered to 215 patients,
RCT + RHT was administered to 79 patients, and RT was used
in 75 patients. Treatment response was evaluated 4–6 weeks
after treatment with TUR-BT.
Results. Complete response (CR) overall was 83% (290/351),
and in treatment groups was RT 68% (45/66), RCT 86%
(178/208), and RCT + RHT 87% (67/77). CR was significantly
improved by concurrent RCT compared with RT (odds ratio
[OR], 2.32; 95% confidence interval [CI], 1.05–5.12; p = .037),
less influenced by hyperthermia (OR, 2.56; 95% CI, 0.88–8.00;
p = .092). Overall survival (OS) after RCT was superior to RT
(hazard ratio [HR], 0.7; 95% CI, 0.50–0.99; p = .045). Five-year
OS from unadjusted Kaplan-Meier estimates was RCT 64%
versus RT 45%. Additional RHT increased 5-year OS to 87%
(HR, 0.32; 95% CI, 0.18–0.58; p = .0001). RCT + RHT compared
with RCT showed a significantly better bladder-preservation
rate (HR, 0.13; 95% CI, 0.03–0.56; p = .006). Median follow-up
was 71 months. The median number of RHT sessions was five.
Conclusion. The multimodal treatment consisted of a maximal
TUR-BT followed by RT; concomitant platinum-based chemo-
therapy combined with RHT in patients with high-grade blad-
der cancer improves local control, bladder-preservation rate,
and OS. It offers a promising alternative to surgical therapies
like radical cystectomy. The Oncologist 2019;24:e1341–e1350
Implications for Practice: Radical cystectomy with appropriate lymph node dissection has long represented the standard of
care for muscle-invasive bladder cancer in medically fit patients, despite many centers reporting excellent long-term results for
bladder preserving strategies. This retrospective analysis compares different therapeutic modalities in bladder-preservation
therapy. The results of this study show that multimodal treatment consisting of maximal transurethral resection of bladder
tumor followed by radiotherapy, concomitant platinum-based chemotherapy combined with regional deep hyperthermia in
patients with Ta, Tis, T1–2 bladder carcinomas improves local control, bladder-preservation rate, and survival. More impor-
tantly, these findings offer a promising alternative to surgical therapies like radical cystectomy. The authors hope that, in the
future, closer collaboration between urologists and radiotherapists will further improve treatments and therapies for the bene-
fit of patients.
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INTRODUCTION
Bladder cancer is among the most common malignant
tumors worldwide and the second leading urological tumor
after prostate cancer.
Radical cystectomy with appropriate lymph node dis-
section has long represented the standard of care for muscle-
invasive bladder cancer in medically fit patients, despite many
centers reporting excellent long-term results for bladder pre-
serving strategies. Cystectomy is associated with postoperative
and perioperative complications of varying severity in up to
64% of patients and mortality rates ranging from 1.5% to 2.7%
[1, 2].
Today, a vast amount of clinical experience from single-
institution trials as well as prospective clinical trials on
primary organ preserving treatment is available [3–6].
Multimodality organ-preservation treatment has become the
treatment of choice for many tumor entities [7–9]. Neverthe-
less, the issue of conservative treatments versus cystectomy
for bladder cancer remains controversial. With the improve-
ments in life expectancy combined with the high prevalence
of concomitant diseases, and with increasing expectations
concerning quality of life, the option of multimodal bladder-
conserving therapy is gaining importance.
A major prerequisite for success is a well-established inter-
disciplinary team that coordinates the multimodal treatment
for patients with bladder cancer. At our hospital, we have
offered patients of all age groups the option of multimodal
bladder-preservation treatment since 1982 [4, 10–14]. In the
early days, all patients were treated with radiotherapy alone.
The treatment was intensified in the nineties through the addi-
tion of concurrent chemotherapy and later through further
addition of regional deep hyperthermia after transurethral re-
section [4, 10, 12]. The aim of this retrospective analysis was
to report the effect of different therapeutic modalities on the
frequency of bladder-preservation, disease-free survival (DFS),
and overall survival.
SUBJECTS, MATERIALS, AND METHODS
Patients
From May 1982 to January 2016, 664 patients underwent
bladder-preservation treatment at our department. A retro-
spective review of these patients with respect to tumor char-
acteristics demonstrated a considerable decrease of advanced
tumor stages T3–4 over the last few years. Therefore, the
patient population for analysis was reduced to patients with
high-risk superficial (Ta, Tis, T1) and muscle-invasive (T2) blad-
der cancer. Among these, 372 of 664 patients had histologi-
cally confirmed pTa, pTis, or pT1–pT2 bladder cancer and no
distant metastases or other concomitant malignancy and
therefore were included. Three of 372 patients were treated
with radiotherapy (RT) + regional deep hyperthermia (RHT)
and thus excluded from analysis. In total, 297 of 369 men and
72 of 369 women constitute the analysis set (ratio 4:1; median
age, 67 years; range, 32–91). For detailed information about
clinical patient characteristics, see Table 1 and Figure 1.
In addition, because of the fact of different prognos-
tic relevance, special attention is given to the groups
non-muscle-invasive bladder cancer (NMIBC) and muscle-
invasive bladder cancer (MIBC; see supplemental online
Figs. 1 and 2).
Exclusion criteria for hyperthermia were metal implants,
severe cardiovascular diseases, and a Karnofsky Performance
Index >1.
Criteria for Toxicity
Adverse hematologic effects were analyzed according to
National Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0 [15]. In addition, the late effects of nor-
mal tissue-subjective, objective, management, and analytic
(LENT-SOMA) grading system was used to examine non-
hematologic toxicity [16].
Treatment
Multimodal treatment starts with transurethral resection of
bladder tumor (TUR-BT), including tumor mapping, with
maximal resection of the gross tumor, if feasible. Residual
tumor status was assessed through biopsies from all re-
section margins: R0 was classified as microscopically com-
plete TUR-BT, R1 indicated microscopic residual tumor, and
R2 indicated macroscopic residual tumor. TNM category
was assigned according to the 1987 edition of the TNM
classification by the International Union Against Cancer and
has been modified according to the 2010 TNM classification
by the American Joint Committee on cancer [17, 18]. All
patients had to have a bladder volume >300 ml.
RT was initiated 4–6 weeks after TUR-BT using 15 MV
photons from a linear accelerator and three-dimensional
conformal treatment planning. A four-field box technique
was usually used, and radiotherapy was administered in
daily fractions of 1.8 Gy on 5 consecutive days each week.
All patients were treated with an empty bladder. Clinical
target volume included the whole bladder, the presacral,
and the internal iliac lymph nodes. The median dose to the
whole bladder and pelvic lymph nodes was 50.4 Gy (range,
16.2–55.8). In case of R0 resection after TUR-BT, the whole
bladder received a boost to 55.8 Gy with a 1.5–2.0 cm
safety margin in all directions. For R1/2 resection, patients
received a 9-Gy boost to the whole bladder to a total dose
of 59.4 Gy. Platinum-based chemotherapy was delivered as
standard chemotherapy and applied simultaneously in the first
and fifth weeks for 5 days each week. In case of mild renal
insufficiency, heart disease, or other concurrent diseases, other
regimes were used. More detailed information on the chemo-
therapy regimen is shown in supplemental online Table 1.
Regional deep hyperthermia was performed once weekly
with the BSD-2000 3D/PC-Hyperthermia System (BSD Medi-
cal Corporation, Salt Lake City, UT). At our hospital, either
Sigma Eye or Sigma-60 applicator was used to emit electro-
magnetic microwave irradiation (90–100 MHz) that sur-
rounds the patient’s pelvic region. The minimum planed
number of hyperthermia treatments was five applications
performed once weekly. Patients were treated while supine
with a circular water pillow used to connect the antenna
power to the patient. After patient positioning, four cali-
brated thermometry probes were located in the bladder
© 2019 The Authors.
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Table 1. Patient characteristics (n = 369)
Characteristics RT RCT RCT + RHT p value
Number of patients, n (%) 75 (20) 215 (58) 79 (21)
Sex, n (%) .217
Male 55 (74) 177 (82) 65 (82)
Female 20 (27) 38 (18) 14 (18)
Age at initial diagnosis, median (range), yr 75 (40–91) 66 (32–87) 67 (38–88) <.001
Median follow-up (months) 40 80 72 .002
Median follow-up (years) 3 7 6 .011
Recurrent tumor, n (%) .539
Primary tumor 62 (83) 165 (76) 60 (76)
Recurrent tumor 13 (17) 49 (23) 19 (24)
Not reported 1 (1)
Median numbers of TUR-BT bevor treatment (range) 1 (1–7) 2 (1–20) 2 (1–10) .042
Histologic subtypes, n (%) .724
Urothelial carcinoma 70 (93) 204 (95) 76 (96)
Squamous cell carcinoma 5 (2) 1 (1)
Urothelial + squamous cell carcinoma 3 (4) 5 (2)
Others 2 (3) 1 (1) 2 (23)
Multifocal growth pattern, n (%) .232
Unifocal 42 (56) 107 (50) 45 (57)
Multifocal 28 (37) 102 (47) 29 (37)
Not reported 5 (7) 6 (3) 5 (6)
Associated carcinoma in situ, n (%) .190
Cis 12 (16) 61 (28) 22 (28)
No cis 53 (71) 142 (66) 57 (72)
Not reported 10 (13) 12 (6)
Median numbers of RHT (range) 5 (1–10)
Pathological T-category (initial TUR-BT), n (%) .004
Ta/Tis 3 (4) 5 (2) 7 (9)
T1 20 (27) 95 (44) 38 (48)
T2 52 (69) 115 (54) 34 (43)
Clinical lymph node classification, n (%) .301
N0 70 (94) 183 (85) 75 (94)
N+ 1 (1) 10 (5) 2 (3)
Not reported 4 (5) 22 (10) 2 (3)
Lymphovascular invasion, n (%) .296
L0 38 (51) 116 (54) 22 (28)
L1 24 (32) 53 (25) 10 (13)
L2 4 (5) 7 (3)
Not reported 9 (12) 39 (18) 47 (59)
Grading, n (%) <.001
G1/2 39 (52) 75 (35) 12 (15)
G3/4 36 (48) 138 (64) 67 (85)
Not reported 2 (1)
Resection margin after initial TUR-BT, n (%) <.001
R0 25 (34) 91 (42) 50 (63)
R1 16 (21) 77 (36) 15 (19)
R2 30 (40) 27 (13) 2 (3)
Not reported 4 (5) 20 (9) 12 (15)
Abbreviations: Cis, carcinoma in situ; RCT, chemoradiotherapy; RHT, regional deep hyperthermia; RT, radiotherapy; TUR-BT, transurethral re-
section of bladder tumor.
© 2019 The Authors.
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cavity, rectum, anal fold, and mouth. Bladder temperature
was measured with a thermistor inserted into the bladder via
a Foley catheter. Throughout the entire treatment, cardiac
function, blood pressure, and oxygen were constantly con-
trolled. Furthermore, patients were requested to make it
known if they experienced any unpleasant sensation sugges-
tive of hot spots, such as burning sensations or pain. Adjust-
ments of treatment settings were changes in power output
per channel, frequency or phase settings, and placement of
additional water boluses. Tolerances for power outputs were
increased up to patients’ compliance. Intravesical and other
temperatures spots were constantly measured every 10 sec-
onds during RHT and for 15 minutes thereafter. Treatment
continued for 60 minutes after bladder temperatures reached
41.5C or for a maximum total duration of 90 minutes, which-
ever was shortest. With the measured intravesical tempera-
tures, the cumulative equivalent minutes at 43C were
calculated as a value in order to describe the thermal dose
applied to the bladder [13, 19, 20]. Radiation started within
an interval of 60 minutes after RHT. Cystectomy was under-
taken in nonresponder patients after TUR-BT re-evaluation. In
case of persistent, extensive associated carcinoma in situ or
recurrent tumor, additional treatments, such as re-TUR-BT
(one or more) with or without topical chemoinstillation for
superficial tumors or salvage cystectomy for muscle-invasive
tumors, were initiated.
Statistical Analysis
Statistical analysis was performed using SPSS v21.0 (SPSS;
Chicago, IL) and R 3.3.3. [21].
Differences between continuous data on clinical patient
characteristics were analyzed using ANOVA on nonmissing
data. The Chi-square test was used to determine statistical
significance between categorical data.
The main characteristics available in the data base that
are important, or have a potential effect on the outcome,
are gender, age (defined as age at time of initial diagnosis),
recurrent tumor, multifocal growth pattern, associated car-
cinoma in situ, histologic grading, tumor stage, lymph node
classification, histologic subtypes, and resection margin.
Complete response determined by control TUR-BT 4–6
weeks following completion of therapeutic modality was
modeled by logistic regression. Overall survival (OS), DFS,
and time to cystectomy were defined from the beginning of
our treatment (determined as the date of initial TUR-BT).
DFS was defined as the absence of locoregional or distant
disease recurrence and death from any cause. All patients
with information on CR were considered (n = 351). Patients
who did not have a complete response (CR) at control TUR-
BT counted as therapy failure and were entered as having
an event at time 0. For OS and DFS, we used Cox models
stratified by therapeutic modalities. Survival curves are
shown for median values of covariates in the whole patient
Figure 1. The flowchart of the trial according to the CONSORT statement.
Abbreviations: M, distant metastasis; RCT, chemoradiotherapy; RHT, regional deep hyperthermia; RT, radiotherapy; TUR-BT, trans-
urethral resection of bladder tumor.
© 2019 The Authors.
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collective. Hazard ratios (HRs) to quantify the treatment
effect are estimated by Cox models adjusted for therapeutic
modality. Reported 5- and 10-year rates are taken from
Kaplan-Meier estimates. In the multivariable models, the var-
iables grading, tumor stage, and resection status have been
included because the patient group has changed consider-
ably over the past years. Further variables were selected for
the multivariable logistic regression model for which p <
.1573 (Akaike criterion) in univariate analysis adjusted for
treatment. The multivariable Cox models contain all variables
of the logistic model plus those variables for which p < .1573
in the respective univariate models stratified by treatment.
Patients with missing values were excluded from the respec-
tive analyses (50 for logistic regression, 62 for OS, and
50 for DFS).
Because of a lack of sufficient data on performance of
cystectomy following RT, especially in the first years of
bladder-preservation treatment in Erlangen (1982 to about
1990), the analysis of time to cystectomy was limited to
294 patients treated with chemoradiotherapy (RCT) or RCT
+ RHT. A total of 240 of 294 patients with nonmissing
covariates were included. Time to cystectomy is regarded
within a competing risk model, with death as competing
endpoint. Hazards are estimated by censoring competing
events stratified by therapeutic modality and adjusted for
covariates predictive for OS or selected by Akaike criterion.
Cumulative incidence curves for the endpoint cystectomy
are shown for median covariate values.
Late treatment-related toxicity is evaluated by Chi-square
tests for the RCT and RCT + RHT groups only because of the
lack of missing blood parameters for patients treated with RT.
RESULTS
Median follow-up of all patients (n = 369) was 71 months,
with a range from 5–336 months. Median follow-up for
patients with high-risk superficial (Ta, Tis, T1) and patients
with muscle-invasive (T2) bladder cancer was 81 months and
61 months. All patients were treated with curative intent.
The median number of hyperthermia treatments was 5
(range, 1–10). The median interval between the initial TUR-
BT and beginning of chemoradiotherapy was 42 days (range,
9–202). The median interval between the end of radiother-
apy and control TUR-BT was 46 days (range, 1–289). Median
covariate values of the whole patient collective, used for
multivariable models, are age = 67 years, tumor = primary,
pT-category = T2, clinical lymph node classification = N0, re-
section status = R1, and histologic grading = G3/4.
Response
Complete response at control TUR-BT was achieved by
290 of 351 patients (83%) which divide into 45/66 (68%),
178/208 (86%), and 67/77 (87%) patients treated with RT,
RCT, and RCT + RHT, respectively. Adjusted CR rates predicted
for median covariate values result to 72%, 86%, and 87% for
RT, RCT, and RCT + RHT. The higher CR rate for RT arises
mainly as the prediction is done for a better resection status
than seen in the RT group.
In subgroup analysis, complete response at control TUR-BT
for patients with high-risk superficial (Ta, Tis, T1) was reached
in 146 of 166 (88%) patients, of whom 19 of 22 (86%) were
treated with RT, 87 of 99 (88%) were treated with RCT, and
40 of 45 (89%) patients were treated with RCT + RHT, respec-
tively. For patients with muscle-invasive (T2) bladder cancer,
the analysis showed a complete response rate of 78%
(144/185). CR was achieved by 26 of 44 (59%), 91 of 109 (84%),
and 27 of 32 (84%) patients for RT, RCT, and RCT + RHT.
Additionally, data analysis of complete remission for
patients with tumor stage T2, R2 resection showed a CR
rate of 38% (9/24), 67% (12/18), and 100% (1/1) for RT,
RCT, and RCT + RHT. For patients with tumor stage T2, R1
resection showed a CR rate of 46% (6/13), 80% (36/45), and
70% (7/10) for RT, RCT, and RCT + RHT.
RCT was superior to RT in the multivariate analysis (OR,
2.32; 95% confidence interval [CI], 1.05–5.12; p = .037).
Additional RHT could not increase the CR rate compared
with RCT and was not statistically significant to RT (OR,
2.56; 95% CI, 0.88–8.00; p = .092; see Table 2).
In the multivariable logistic regression, R2-resection (OR,
0.24; 95% CI, 0.10–0.55; p < 0001) and primary tumor (OR,
0.34; 95% CI, 0.16–0.71; p = .004) were significantly associ-
ated with CR. The variable grading (p = .348) and pT category
(p = .053) were included in the multivariable model because
the patient group had changed considerably over the past
years. None of these factors reached statistical significance.
Overall Survival
The 5- and 10-year overall survival for RCT were 64% (95%
CI, 58%–71%) and 39% (95% CI, 33%–47%) and for RT were
45% (95%CI, 35%–58%) and 19% (95% CI, 12%–30%); addi-
tional hyperthermia further increased the 5- and 10-year
OS to 87% (95% CI, 79%–95%) and 60% (95% CI, 47%–77%).
In the subgroup analysis, patients with NMIBC, the 5-year
overall survival for RCT was 75% (95% CI, 67%–84%) and for
RT was 59% (95% CI, 42%–84%); additional hyperthermia fur-
ther increased the 5-year OS to 94% (95% CI, 87%–100%).
For patients with MIBC, the 5-year overall survival for RCT
was 57% (95% CI, 48%–67%) and for RT was 43% (95% CI,
31%–61%); additional hyperthermia further increased the
5-year OS to 77% (95% CI, 63%–94%).
In the multivariate analysis for the whole group, RCT was
superior to RT (HR, 0.70; 95% CI, 0.50–0.99; p = .045); com-
bined RHT increased OS (HR, 0.32; 95% CI, 0.18–0.58; p =
.0001) as well (see Table 3). Figure 2 show OS curves adjusted
for median patient characteristics stratified by therapeutic
modality, Please note that adjustment achieves comparability
of treatment effects but affects the curves which thus devi-
ate from 5- and 10-year rates from Kaplan-Meier estimates.
Furthermore, HRs and p values in Table 3 for treatment
effects are given for an adjusted Cox model and are not strat-
ified by treatment and therefore do not directly correspond
to differences in plotted survival curves.
Redefinition of the reference treatment group in multi-
variate analysis showed a significantly better OS through
the addition of hyperthermia to chemoradiotherapy (RCT +
RHT vs. RCT: HR, 0.46; 95% CI, 0.27–0.78, p = .004).
Disease-Free Survival
Cumulative estimated DFS for RCT (40%; 95% CI, 34%–47%
and 24%; 95% CI, 18%–30%) was superior to RT (20%; 95%
© 2019 The Authors.
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CI, 12%–32% and 6%; 95% CI, 2%–16%) for 5- and 10-year as
well as in multivariate analysis (HR, 0.70; 95% CI, 0.50–0.98;
p = .039), respectively. Additional hyperthermia further
increased the 5- and 10-year DFS to 66% (95% CI, 55%–78%)
and 46% (95% CI, 34%–62%) in multivariate analysis (HR,
0.39; 95% CI, 0.24–0.64; p = .0001; see supplemental online
Fig. S3 and supplemental online Table 2).
In addition to this analysis, DFS for patients with NMIBC
for RCT was 46% (95% CI, 37%–57%) and for RT was 14% (95%
CI, 5%–39%); additional hyperthermia further increased the
5-year DFS to 70% (95% CI, 57%–86%). For patients with MIBC,
the 5-year DFS for RCT was 34% (95% CI, 26%–44%) and for
RT was 23% (95% CI, 13%–39%); additional hyperthermia fur-
ther increased the 5-year DFS to 60% (95% CI, 45%–81%).
Table 3. Analysis of influence in patients and therapy-related parameters to overall survival, results of univariate and
multivariate Cox regressions stratified by therapeutic modality (unless otherwise stated)
Variable and category
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Treatmenta
RCT vs. RT 0.52 (0.39–0.69) <.001 0.70 (0.50–0.99) .045
RCT + RHT vs. RT 0.25 (0.15–0.40) <.001 0.32 (0.18–0.58) .0001
Gender; female vs. male 1.17 (0.86–1.06) .315
Age at diagnosis per yr 1.05 (1.04–1.06) <.001 1.05 (1.03–1.06) <.0001
Recurrent tumor vs. primary tumor 1.35 (1.00–1.81) .052 1.52 (1.08–2.13) .017
Histologic subtypes;
nonurothelial vs. urothelial carcinoma
0.96 (0.56–1.66) .89
Multifocal vs. unifocal growth pattern 1.19 (0.92–1.54) .19
No cis vs. cis 1.00 (0.74–1.34) .98
pT category; T2 vs. Ta/Tis/T1 1.04 (1.01–1.06) .004 1.32 (0.99–1.76) .058
Clinical lymph node classification; N+ vs. N0 2.06 (1.08–3.92) .027 2.04 (0.97–4.26) .059
Resection status
R1 vs. R0 1.55 (1.15–2.08) .004 1.46 (1.06–2.02) .022
R2 vs. R0 1.71 (1.19–2.44) .004 1.32 (0.90–1.93) .152
Histologic grading; G3/4 vs. G1/2 1.00 (0.77–1.30) .995 0.86 (0.64–1.16) .31
aResults for Cox regression adjusted for therapeutic modality.
Abbreviations: CI, confidence interval; cis, associated carcinoma in situ; HR, hazard ratio; RCT, chemoradiotherapy; RHT, regional deep hyper-
thermia; RT, radiotherapy.
Table 2. Analysis of influence in patients and therapy-related parameters on complete response, results of univariate and
multivariate logistic regressions
Variable and category
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Treatment
RCT vs. RT 2.77 (1.44–5.28) .002 2.32 (1.05–5.12) .037
RCT + RHT vs. RT 3.13 (1.38–7.52) .008 2.56 (0.88–8.00) .092
Gender; female vs. male 1.22 (0.60–2.66) .597
Age at diagnosis per yr 0.97 (0.94–1.00) .030 0.97 (0.94–1.01) .122
Recurrent tumor vs. primary tumor 0.41 (0.22–0.77) .005 0.34 (0.16–0.71) .004
Histologic subtypes; nonurothelial
carcinoma vs. urothelial carcinoma
0.75 (0.25–2.77) .631
Multifocal vs. unifocal growth pattern 0.75 (0.41–1.36) .340
No cis vs. cis 1.18 (0.60–2.25) .612
pT category; T2 vs. Ta/Tis/T1 0.95 (0.89–0.99) .053 0.59 (0.29–1.17) .134
Clinical lymph node classification; N+ vs. N0 0.55 (0.16–2.59) .394
Resection status
R1 vs. R0 0.57 (0.26–1.22) .143 0.63 (0.29–1.40) .255
R2 vs. R0 0.20 (0.09–0.45) <.001 0.24 (0.10–0.55) <.001
Histologic grading; G3/4 vs. G1/2 0.74 (0.39–1.37) .348 0.68 (0.32–1.38) .297
Abbreviations: CI, confidence interval; cis, associated carcinoma in situ; OR, odds ratio; RCT, chemoradiotherapy; RHT, regional deep hyperther-
mia; RT, radiotherapy.
© 2019 The Authors.
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Patients with R1 or R2 resections or recurrent tumors
had a significantly higher risk of experiencing an event.
Additionally, tumor stage and grading were included
because of the selection strategy after p value. In addition,
the multivariate analysis with redefined reference treat-
ment showed a significantly longer period of DFS through
the addition of hyperthermia to chemoradiotherapy (RCT +
RHT vs. RCT: HR, 0.56; 95% CI, 0.37–0.85; p = .006). In mul-
tivariate analysis, age (p < .0001), primary tumor (p = .005),
and resection status (R2 vs. R0, p = .002) were significant
predictors for extended DFS.
Cystectomy-Free Survival
Overall, 55 patients who received RCT or RCT + RHT had to
be treated with cystectomy following bladder conserving
treatment. Most of these cases were due to tumor progres-
sion, with very few patients requiring a cystectomy due to
therapeutic side effects (in particular bladder shrinking).
Comparing the treatment group RCT + RHT to RCT showed
a significantly better 5- and 10-year bladder-preservation rate
(96% vs. 82% and 96% vs. 78%, see Fig. 3; Cumulative inci-
dence = 100% bladder-preservation rate); this was also shown
in multivariate analysis (HR, 0.13; 95% CI, 0.03–0.56; p = .006)
compared with RCT.
In the multivariate analysis, only resection status (R2 vs.
R0; HR, 2.57; 95% CI, 1.05–6.30; p = .039) reached statistical
significance with respect to the risk of cystectomy (see
Table 4).
Acute Treatment-Related Toxicities
In patients treated with RCT or RCT + RHT, some mild
to moderate treatment-related side effects (grades 1–2)
were observed. These included transient cystitis, enteritis,
and nausea and were managed by symptomatic treatment.
Grade 3 acute toxicity occurred as leucopenia in 25%
(54/215) for RCT and 11% (9/79) for RCT + RHT and as
thrombocytopenia in 6% (12/215) for RCT and 3% (2/79) for
RCT + RHT. Grade 4 toxicity was especially limited to hemato-
logical side effects (i.e., leucopenia) in 2% (5/215) for RCT
and 3% (2/79) for RCT + RHT and as thrombocytopenia in 2%
(4/215) for RCT and 1% (1/79) for RCT + RHT. Grade 3 bladder
toxicities was reported in 6% (13/215) for RCT and 5% (4/79)
for RCT + RHT.
A total of 1.3% (1/79) of patients from the RCT + RHT
group and 1.8% (4/215) from the RCT group had grade
4 bladder toxicities. Life-threatening bleeding, infections, or
treatment-related deaths were not seen (see supplemental
online Table 3).
Late Treatment-Related Toxicity
No side effects (grade 0) were seen in 61% (130/215) of
patients for RCT and 32% (25/79) for RCT + RHT. Mild dys-
uria, nocturia, urgency, proctitis, and diarrhea (grade 2) were
recorded in 2%–13% for RCT and 2%–22% for RCT + RHT.
In 14 of 215 patients for RCT and 17 of 79 for RCT +
RHT, late toxicity was not documented. A total of 1.3%
(1/79) of patients from the RCT + RHT group and 2.3%
(5/215) from the RCT group underwent cystectomy because
of a shrinking bladder. Reduced bladder capacity (100–200
ml) with <2-hour intervals of micturition was seen in 10%
(22/215) for RCT and 15% (12/79) for RCT + RHT. Five
patients experienced late grade 4 gastrointestinal toxicity
and required surgical intervention (see supplemental online
Table 4).
DISCUSSION
The present retrospective analysis compares different ther-
apeutic modalities in bladder-preservation therapy, imple-
mented in the 1980s and 1990s in Erlangen [10, 11]. To our
knowledge this is the largest investigation comparing various
Figure 2. Overall survival adjusted for median patient charac-
teristics stratified by therapeutic modality.
Abbreviations: RT, radiotherapy; RCT, chemoradiotherapy; RHT,
regional deep hyperthermia; TUR, transurethral resection.
Figure 3. Cumulative incidence for competing event cystectomy
in patients after multimodal bladder-preserving treatment,
stratified by the two different therapeutic modalities.
Abbreviations: RCT, chemoradiotherapy; RHT, regional deep
hyperthermia; RT, radiotherapy; TUR, transurethral resection.
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methods of bladder preservation. Concomitant chemotherapy
in addition to radiotherapy significantly improved OS, the rate
of CR, and extended DFS in patients with bladder cancer [22].
The current follow-up evaluation of our database was
confined to the subgroup of Ta, Tis, and T1–2 bladder carci-
nomas. Addition of hyperthermia to chemoradiotherapy does
not seem to increase CR but leads to a significant reduction
in salvage cystectomy, improving OS and DFS.
One of the aims of this retrospective study is to show the
historical development of multimodal bladder-preservation
therapy. In our multivariate analysis, the complete response
for NMIBC versus MIBC was not significantly different but
reached borderline significance with p = .053. This might be
explained by the different complete remission rates for MIBC
in the radiotherapy only group and shows the need for con-
comitant chemotherapy, especially in the group of patient
with T2 bladder cancer.
Furthermore, in the RCT and RCT plus HT group, there
was no significant difference in complete remission regard-
ing MIBC versus NMIBC, but intensification of treatment
(addition of chemotherapy  hyperthermia) improved OS
and DFS.
Regarding the small number of patients with R2 status
who were treated with hyperthermia, data are difficult to
interpret between different treatment groups, but we would
conclude that tumors in the RCT group were not more
advanced because of less aggressive TUR-BTs.
Our analysis intends to contribute to the discussion of
when bladder-preservation therapy in high-risk bladder can-
cer is possible. Cystectomy, with or without neoadjuvant
therapy, as well as various bladder-preservation therapies
are proven effective for the treatment of bladder cancer [4,
10, 12, 23]. Nevertheless, a direct comparison between
bladder-preservation modalities and radical cystectomy is
difficult because of the lack of sufficiently sized randomized
studies. For this reason, the use of retrospective data collec-
tions such as ours is necessary for comparison between dif-
ferent therapeutic modalities.
Bladder-preservation strategies are often considered to
be inferior to cystectomy, and radical cystectomy with pel-
vic lymphadenectomy is nowadays considered the “gold
standard” treatment for muscle-invasive bladder cancer.
Recurrence-free survival of 73% and a 5-year survival rate
of 62%–68% after radical cystectomy for all tumor stages
are described in the literature [24, 25]. In high-risk tumor
stages, 5-year OS ranges from 65% to 82% [26, 27]. Also, in a
subgroup analysis of pT2 bladder cancer, subsequent recur-
rence-free survival of 86% in lymph node (LN)-negative versus
38% in LN-positive patients and 5-year cancer-specific survival
of 85% versus 60% are demonstrated [28].
According to the literature, only 10%–30% of patients
with bladder cancer are treated with a multimodal therapy
concept for organ preservation [29–31]. Several meta-
analyses summarized data from previous trials of bladder
preserving therapy [3, 5, 32]. A recent meta-analysis of
combined chemoradiotherapy by Arcangeli et al. reported
78% CR, 28% muscle infiltrating recurrence, and 21% salvage
cystectomy in patients with all tumor stages of bladder cancer
[32]. The 5-year OS was 56%. These results are in line with
our findings for concurrent chemoradiotherapy, but, of note,
in our analysis, only Ta, Tis, T1-T2 tumor stages were included.
With the addition of hyperthermia, the 5-year salvage
cystectomy rate could be improved by 14%, and the 5-year OS
rate was 87% (i.e. higher than in most series with cystectomy).
It is well known from the literature that hyperthermia is able
to improve the efficacy of radio- and chemotherapy in many
different tumor entities [25–27, 33, 34]. Synergy effects also
result from the spatial interaction between chemotherapy and
Table 4. Analysis of influence in patients and therapy-related parameters to cystectomy-free survival, results of univariate
and multivariate Cox regressions for hazard of cystectomy stratified by therapeutic modality (unless otherwise stated)
Variables and category
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Treatment; RCT + RHT vs. RCT 0.09 (0.02–0.38) .001 0.13a (0.03–0.55) .006
Gender; female vs. male 1.10 (0.55–2.19) .783
Age at diagnosis per yr 0.99 (0.97–1.02) .650 0.99 (0.97–1.02) .680
Recurrent tumor vs. primary tumor 1.51 (0.83–2.74) .170 1.53 (0.73–3.19) .256
Histologic subtypes; nonurothelial
vs. urothelial carcinoma
1.72 (0.62–4.78) .296
Multifocal vs. unifocal growth pattern 1.29 (0.76–2.20) .345
No cis vs. cis 0.80 (0.45–1.42) .439
pT category; T2 vs. Ta/Tis/T1 1.86 (1.08–3.22) .025 1.80 (0.94–3.45) .076
Clinical lymph node classification; N+ vs. N0 1.07 (0.26–4.41) .926 0.56 (0.08–4.20) .574
Resection status
R1 vs. R0 1.83 (0.97–3.45) .064 1.77 (0.90–3.49) .097
R2 vs. R0 3.22 (1.42–7.29) .005 2.57 (1.05–6.30) .039
Histologic grading; G3/4 vs. G1/2 1.45 (0.80–2.63) .224 1.56 (0.78–3.09) .205
aResults for Cox regression adjusted for therapeutic modality. This hazard ratio has the reference RCT and is therefore not comparable to the
other hazard ratios for disease-free survival and overall survival with reference radiotherapy.
Abbreviations: CI, confidence interval; cis, associated carcinoma in situ; HR, hazard ratio; RCT, chemoradiotherapy; RHT, regional deep
hyperthermia.
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hyperthermia because most cytostatic drugs work better in
areas with good blood flow, and hyperthermia is more effec-
tive in hypoxic tumor areas [25].
There are only few data available on hyperthermia in
patients with bladder cancer [35]. A randomized study by
Colombo et al. showed a reduction of local recurrence in a
2-year follow-up in patients with (Ta-T1) high-risk bladder
cancer. The recurrence rate was significantly lower in the
chemotherapy group with intravesical hyperthermia (17.1%),
as compared with the Mitomycin C alone group (57.5%) [36].
This method has not been taken up widely because of a high
rate of side effects [37, 38].
Wittlinger et al., in 2009, reported the first data from
Erlangen on hyperthermia in combination with chemora-
diotherapy. As expected, the high rate of complete remission
of 96% could not be maintained [13].
The Dutch Deep HT Group presented a randomized study
for radiotherapy and hyperthermia in pelvic tumors, includ-
ing bladder carcinomas. This trial has shown improved local
tumor control without an increase in OS [39]. One explana-
tion for the improved on DFS in our study is that hyperther-
mia activates the immune system through cell membrane
changes [40, 41]. Another aspect is the effective heating of
urine without much heat loss.
Evidently, our retrospective analysis has some limitations.
As a result, the main risk factors are not homogeneously dis-
tributed among treatment groups. For example, more patients
with T2 tumor stage were treated with RT, whereas more
patients with poorly differentiated bladder cancer G3/4 were
treated with RCT or RCT + RHT. Moreover, our analysis includes
a time period during which patients did not receive uniform
staging and during which combined chemoradiotherapy
were not standard procedure. The development of tech-
nology in the past years has led to dose escalation, reduction
of toxicity because of optimization of patient positioning,
and improved protection of normal tissues [42]. Further-
more, research has led to major advances in clinical medi-
cine with the use of new molecular targets and the
developments of modern chemotherapy regimens. Finally,
we excluded patients with T3–4 tumors from the analysis,
because bladder-preserving treatment of patients with this
tumor stage has declined significantly in recent years.
RCT with or without combined RHT was well tolerated.
However, it should be mentioned that the late side effects
for bladder function were assessed retrospectively from
patient records. Therefore, micturition disorders or function
diagnostics that are not documented cannot be taken into
account, leading to an underestimation of late side effects
in this analysis.
The median age of patients with multimodal treatment
was higher than that of patients undergoing radical
cystectomy alone. However, many publications on bladder
preserving therapy have shown similar results with respect to
OS and DFS [43]. This is partly due to the fact that radical
cystectomy is associated with increased risks and postopera-
tive complications in elderly patients. Therefore, we can con-
firm that radiotherapy with or without hyperthermia could
also be performed in elderly patients and improves the poten-
tial to spare the native bladder.
CONCLUSION
The multimodal treatment concept for bladder preservation
is a safe and effective therapy with excellent CR rates and
overall survival and is associated with acceptable toxicity. It
offers a promising alternative to surgical therapies like radical
cystectomy. It should therefore be an important objective to
closely collaborate with urologists to improve treatments and
therapies for the benefit of patients.
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